Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. director Douglas Forsyth received a grant of stock options covering 15,000 shares of Common Stock. The options have an exercise price of $95.22 per share and expire on June 3, 2036.

According to the filing, the stock option will become fully exercisable on June 3, 2027, subject to Forsyth’s continued service through that date. Following this award, he holds 15,000 stock options directly, and the transaction reflects compensation rather than an open‑market purchase or sale.

Insights

Equity compensation analyst

Director received a routine stock option grant as equity compensation, with no open-market buying or selling.

Director Douglas Forsyth was granted stock options for 15,000 shares of Inhibrx Biosciences Common Stock at an exercise price of $95.22 per share. The transaction is coded as an acquisition via grant, not an open-market trade.

The options become fully exercisable on June 3, 2027, contingent on continued service, and expire on June 3, 2036. This aligns with standard long-term incentive design, tying compensation to future share price performance over a multi-year horizon.

Following the grant, Forsyth holds 15,000 options directly, and there are no additional derivative positions shown in this filing. The filing does not indicate any concurrent stock sales or tax-withholding events, reinforcing that this is a straightforward equity award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FORSYTH DOUGLAS

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 15,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 15,000 options Exercise price: $95.22 per share Vesting date: June 3, 2027 +2 more

5 metrics

Stock options granted 15,000 options Grant to director Douglas Forsyth

Exercise price $95.22 per share Strike price of option grant

Vesting date June 3, 2027 Date options become fully exercisable

Expiration date June 3, 2036 Option term end

Options held after grant 15,000 options Total derivative holdings after transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, Common Stock

4 terms

Stock Option (right to buy) financial

"Security title is listed as "Stock Option (right to buy)" for this grant."

exercise price financial

"The conversion or exercise price of the option is 95.2200 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The option’s expiration date is stated as June 3, 2036 in the data."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Stock financial

"The underlying security title for this option grant is Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FORSYTH DOUGLAS

(Last) (First) (Middle)

C/O INHIBRX BIOSCIENCES, INC.

11025 NORTH TORREY PINES ROAD, SUITE 140

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibrx Biosciences, Inc. [ INBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$95.22	06/03/2026		A		15,000		06/03/2027(1)	06/03/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Remarks:

	/s/ Kelly D. Deck, as attorney-in-fact for Douglas G. Forsyth	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Inhibrx Biosciences (INBX) director Douglas Forsyth receive in this Form 4?

Director Douglas Forsyth received a grant of stock options for 15,000 shares of Inhibrx Biosciences Common Stock. These options are a form of equity compensation, not an open-market purchase or sale of existing shares.

What is the exercise price of Douglas Forsyth’s Inhibrx (INBX) stock options?

The stock options granted to Douglas Forsyth have an exercise price of $95.22 per share. This means he can buy Inhibrx Common Stock at that price once the options become exercisable, regardless of the future market price.

When do Douglas Forsyth’s Inhibrx (INBX) stock options vest and become exercisable?

Forsyth’s stock option will be fully exercisable on June 3, 2027, provided he continues to serve through that date. Until then, the option remains unexercised and represents a future right to buy shares at the set exercise price.

When do the Inhibrx (INBX) stock options granted to Douglas Forsyth expire?

The options granted to Douglas Forsyth expire on June 3, 2036. After that expiration date, any unexercised portion of the 15,000-share option grant will lapse, and he will no longer be able to purchase shares under this award.

Does this Inhibrx (INBX) Form 4 show any stock sales by Douglas Forsyth?

The Form 4 reports only a grant of stock options to acquire 15,000 shares and no stock sales. The transaction code reflects a grant or award, indicating compensation rather than an open-market sale or purchase of Inhibrx shares.

How many Inhibrx (INBX) options does Douglas Forsyth hold after this transaction?

After this transaction, Douglas Forsyth holds 15,000 stock options directly, as shown by the total shares following the transaction. These options all relate to this new award and are tied to the $95.22 exercise price and 2036 expiration date.